Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 form a heterodimer and mediate receptor interactions and viral fusion. Both E1 and E2 are targets of the neutralizing antibody (NAb) response and are candidates for the production of vaccines that generate humoral immunity. Previous studies demonstrated that N-terminal hypervariable region 1 (HVR1) can modulate the neutralization potential of monoclonal antibodies (MAbs), but no information is available on the influence of HVR2 or the intergenotypic variable region (igVR) on antigenicity. In this study, we examined how the variable regions influence the antigenicity of the receptor binding domain of E2 spanning HCV polyprotein residues 384 to 661 (E2 661 ) using a panel of MAbs raised against E2 661 and E2 661 lacking HVR1, HVR2, and the igVR (⌬123) and well-characterized MAbs isolated from infected humans. We show for a subset of both neutralizing and nonneutralizing MAbs that all three variable regions decrease the ability of MAbs to bind E2 661 and reduce the ability of MAbs to inhibit E2-CD81 interactions. In addition, we describe a new MAb directed toward the region spanning residues 411 to 428 of E2 (MAb24) that demonstrates broad neutralization against all 7 genotypes of HCV. The ability of MAb24 to inhibit E2-CD81 interactions is strongly influenced by the three variable regions. Our data suggest that HVR1, HVR2, and the igVR modulate exposure of epitopes on the core domain of E2 and their ability to prevent E2-CD81 interactions. These studies suggest that the function of HVR2 and the igVR is to modulate antibody recognition of glycoprotein E2 and may contribute to immune evasion.
H
epatitis C virus (HCV) infects between 150 million to 200 million people worldwide and is now the leading indicator for liver transplants in developed countries. While direct-acting antiviral drugs have elevated the sustained virological response rate, their high cost and the need to identify those people infected with HCV remain major impediments to their widespread use to eradicate HCV. Vaccines remain the most effective way to prevent the spread of infectious diseases, yet there is no prophylactic vaccine for HCV. One of the major limitations to the design of an HCV vaccine is the need to afford protection against the 7 circulating genotypes and the Ͼ67 subtypes, which differ by up to 30% and 20%, respectively, at the nucleotide level.
Neutralizing antibodies (NAbs) are key components of all available vaccines. Both polyclonal and monoclonal NAbs can prevent HCV infection of experimental animals and have been implicated in playing a major role in viral clearance in natural HCV infection (1) (2) (3) (4) (5) (6) . The major target of the antibody response to HCV infection is glycoprotein E2, which mediates direct proteinprotein interactions with tetraspanin CD81 and scavenger receptor class B type I (7, 8) . The receptor-binding domain (RBD) of E2 extends from HCV polyprotein residues 384 to 661 (E2 661 ) (9) and contains 4 discrete regions involved in CD81 binding as well as three hypervariable regions (HVRs) ( Fig. 1) (9) . Hypervariable region 1 is located at the N terminus of E2 and elicits type-specific NAbs with little ability to cross-neutralize heterologous strains (10) . A function of HVR1 may be to modulate the exposure of the CD81-binding site and the ability of antibodies to mediate the neutralization of HCV (11) . Hypervariable region 2 (HVR2) and the intergenotypic variable region (igVR) form surface-exposed loops but do not represent targets of the NAb response ( Fig. 1A and B). All three variable regions can be deleted from intact wildtype (WT) E2 661 to yield a minimized form of the glycoprotein (⌬123) that retains NAb epitopes and the ability to bind CD81 (12) (Fig. 1A) .
Recently, two crystal structures of an E2 core domain in complex with monoclonal antibodies (MAb) were solved to reveal the conformation of the CD81 binding site on the neutralizing face of the glycoprotein. Unlike glycoprotein E of the phylogenetically related flaviviruses, HCV E2 does not have a three-domain architecture typical of class II fusion proteins. Instead, E2 adopts a compact globular immunoglobulin-like fold comprising a central ␤ sandwich surrounded by short front and back layers comprising loops, short helices, and ␤ sheets (13, 14) . The immunoglobulin sandwich is formed by 4 ␤ strands that form an inner sheet and 2 solvent-exposed ␤ strands that comprise the outer sheet. A loop connecting the inner and outer sheets contains many of the key CD81 binding residues and is adjacent to the front layer, where additional surface-exposed CD81 contact residues are found (Fig. 1B) . This region of E2 was termed the neutralizing face, as many of the NAbs directed toward E2 bind this region and have the ability to inhibit CD81 binding. The igVR forms a disulfide-constrained loop within a flexible region spanning residues 567 to 596. However, threedimensional (3D) structural information was not obtained for HVR1 or the adjacent epitope spanning residues 412 to 421 recognized by broadly neutralizing E2-CD81-blocking antibodies. HVR2, also absent from the E2 core domain crystal structures, resides within a highly flexible region on the nonneutralizing face of E2. In the case of the region spanning residues 412 to 421, structural information has been obtained by using MAbs bound to peptide analogs, revealing that it can adopt multiple conformations and suggesting a degree of conformational flexibility (15) (16) (17) (18) .
We previously proposed that the three variable regions could shield the underlying E2 core domain, providing a mechanism whereby the virus can modulate the exposure of conserved neu- 661 , and E2 661 variants with deletions of HVR1 (⌬1), HVR2 (⌬2), the igVR (⌬3), or combinations thereof (⌬12, ⌬13, ⌬23, and ⌬123). HVR2 and the igVR were replaced with a GSSG linker. Numbering is done according to the H77c prototype strain. Epitope I, II, and III regions are underlined on the E2 structure and overlap CD81 binding sites, shown in blue, orange, and green. A fourth region (yellow) is also implicated in CD81 interactions. Hypervariable region 1, HVR2, and the igVR are shown in red. The transmembrane domain and the C-terminal stem region are shown in black and gray, respectively, on the full-length E2 schematic. (B) Cartoon drawing of the E2 core domain with its surface overlaid (PDB accession number 4MWF) (13) . Coloring is according to that described above for panel A. The predicted location of the region spanning residues 411 to 420 (purple) that overlaps epitope I and precedes HVR1 is shown. tralization epitopes (12) . In this study, we produced and characterized a panel of MAbs to E2 661 and ⌬123 and used well-characterized human MAbs in order to examine how the variable regions modulate the exposure of both neutralizing and nonneutralizing epitopes on E2 and examined antigenic differences between intact E2 and the ⌬123 core domain. Our results indicate that ⌬123 has different antigenic properties from those of intact E2 661 , related to the absence of three variable regions, and suggest that the variable regions can occlude the underlying CD81 binding site on the conserved core domain. In addition, our data suggest that there is an interaction between HVR1, HVR2, and the igVR that is not predicted from the three-dimensional structure of the E2 core domain monomer. These data suggest that all three variable regions alter both the structure and the accessibility of the CD81 binding site on E2 and modulate the presentation of neutralizing and nonneutralizing epitopes in E2.
MATERIALS AND METHODS
Vectors. The codon-optimized DNA sequence encoding H77c E2 661 was synthesized (GeneArt, Invitrogen, CA, USA) and contained an N-terminal human trypsin leader sequence and a C-terminal 6ϫHis tag. The H77c E2 661 clones containing deletions of HVR1 (⌬1); HVR2 (⌬2); igVR (⌬3); HVR1 and HVR2 (⌬12); HVR1 and the igVR (⌬13); HVR2 and the igVR (⌬23); or HVR1, HVR2, and the igVR (⌬123) were constructed by using overlap extension PCR. The region encoding HVR1 (residues 387 to 408) was deleted, while the regions encoding HVR2 (residues 460 to 485) and the igVR (residues 570 to 580) were replaced with a GSSG linker sequence. A codon-optimized DNA sequence encoding H77c E2 661 was used as the template, and the products were cloned into pcDNA3.1 and sequenced by using BigDye Terminator chemistry. The DNA sequences encoding E2 661 of H77c (GenBank accession number AF009606) (genotype 1a [G1a]), Con1 (accession number AJ238799) (G1b), JFH1 (accession number AB047639) (G2a), J6 (accession number AF177036) (G2a), S52 (accession number GU814263) (G3a), ED43 (accession number GU814265) (G4a), SA13 (accession number AF064490) (G5a), and EUHK2 (accession number Y12083) (G6a) were synthesized (GeneArt, Invitrogen, CA, USA) and cloned into a pcDNA3 expression vector with an N-terminal leader sequence and a C-terminal 6ϫHis tag, as described previously (19) .
For epitope mapping using H77c E2 661 proteins, 36 single amino acids (implicated in CD81 binding or NAb recognition) were mutated to alanine or another amino acid. Twenty-seven mutations were generated by overlap extension PCR using the codon-optimized DNA sequence encoding H77c E2 661 to generate single point mutants of E2 661 proteins, including Q412A, L413A, N415A, N417A, G418A, W420A, W420F, H421A,  N423A, S424A, L427A, N430A, W437F, G523A, P525A, P525G, Y527A,  W529A, W529F, G530A, D535A, N540A, W549A, W549F, Y613A,  W616A , and W616F, and contained a C-terminal 6ϫHis tag. Previously described E2 661 -Myc constructs with the mutations G436A, W437A, L438A, A439P, A439S, G440A, L441A, F442A, and Y443A were reamplified such that the C-terminal Myc epitope tag was replaced with a 6ϫHis sequence and sequenced by using BigDye Terminator chemistry (20) .
Expression vectors for the production of infectious retroviruses pseudotyped with E1E2 heterodimers (HCVpp) from G1a (pE1E2H77c) were constructed as described previously (21) . Cell culture-derived HCV (HCVcc) was produced from full-length in vitro-transcribed RNA transfected into human hepatoma Huh7. 5 (24) , encompassing the gagpol-vif-vpr-vpu region, was ligated into the corresponding restriction sites of pcDNA3.1 to give pcNL4.3GagPolVVV. Three tandem termination codons were introduced immediately 3= of the NdeI site present in vif (nt 5121 [underlined]) using pNL4.3 as the template and the primers 5=-TTCCATATGTAATGATAG AGGAAAGCTAAGGAC and 5=-TTTTCTGGATCCCTACAGATCATC AATATCCCAAGG in a PCR. The mutated PCR product (spanning the vif-vpr-vpu region) was end filled by using the Klenow fragment of Escherichia coli DNA polymerase I and ligated into the NdeI-EcoRV sites present in pcNL4.3GagPolVVV. A termination codon was then introduced immediately 3= of the initiation codon of vpr in pcNL4.3Gag PolVVV by the Quickchange XLII mutagenesis method (Agilent Technologies, CA, USA) using the primers 5=-GGAAACTGACAGAGGACAGAT GTAATAAGCCCCAGAAGACCAAGGGCCAC and 5= -GTGGCCCTTGGTCTTCTGGGGCTTATTACATCTGTCCTCTGTCA GTTTCC to give pcGagPolVpu. Finally, the Rev-responsive element was PCR amplified by using pNL4.3 as the template and the primers 5=-AAA AGGCCTTCTAGACCAAGGCAAAGAG and 5=-AAAAGGCCTTCTAG AAGCATTCCAAGGCAC and ligated into the unique XbaI site of pcNL4.3GagPolVpu to give pcNL4.3GagPolVpu RRE . The vector used to express the large extracellular loop (LEL) residues 113 to 201 of CD81 as a maltose-binding protein (MBP) fusion (MBP-LEL 113-201 ) was previously described (19) . Cell lines, transfections, and protein expression. Human embryonic kidney HEK293T cells were maintained in Dulbecco's modified Eagle medium (Invitrogen, CA, USA) containing 10% heat-inactivated fetal bovine serum (FBS) (Invitrogen, CA, USA), 2 mM L-glutamine (GE Healthcare, United Kingdom), 1 M HEPES buffer solution (Invitrogen, MA, USA), 0.1 mg/ml gentamicin antibiotic (Invitrogen, CA, USA), and 1 g/ml minocycline hydrochloride salt (Sigma-Aldrich, MO, USA) (DMF10). Huh7.5 cells were used for infection assays and maintained in DMF10 medium for HCVpp or in DMF10 medium supplemented with 10 mM nonessential amino acids (DMF10NEAA) for HCVcc. Cells were incubated at 37°C with 5% CO 2 . Transfections were performed by using Fugene 6 (Promega, Madison, WI, USA) or calcium phosphate for DNA or DMRIE-C (Life Technologies, CA, USA) for RNA, according to the manufacturer's recommendations.
Virus-like particles (VLPs) were produced by transfecting HEK293T monolayers with pE1E2H77c, pNL4.3GagPolVpu RRE , and pCMV-rev (NIH AIDS Reagent Program) at a 1:1:0.6 ratio of DNA using polyethylenimine (PEI; Polysciences, Inc., USA).
E2 661 glycoproteins and variants of E2 661 containing variable region deletions were expressed in HEK293T cells as described previously (12, 19, 20) . Alternatively, glycoproteins were produced by transfecting 25 g of plasmid DNA in 160 l of 2 M calcium phosphate in HEPES-buffered saline (pH 7.0) and applied to 80% confluent HEK293T cells in 175-cm 2 flasks. Tissue culture medium was replaced 24 h later with Opti-MEM (Life Technologies, CA, USA), and tissue culture fluid containing secreted glycoproteins was harvested daily for up to 5 days and concentrated in a Amicon YM30 ultrafiltration device (Merck-Millipore, Darmstadt, Germany). Alternatively, 105 g PEI was mixed with 35 g of DNA and applied to 80% confluent HEK293T cells in T175 flasks. The cell culture supernatant was replaced with Opti-MEM after 4 h of transfection. Tissue culture fluid containing the secreted glycoproteins were harvested daily for up to 5 days and concentrated with a 30,000-molecular-weight-cutoff (MWCO) centrifugal unit (Vivaproducts, MA, USA).
Antibodies. MAbs H53, H52, and A4 were kind gifts from Jean Dubuisson and Harry Greenberg (25, 26) . MAbs HC1 (27) and HC84.22 were kind gifts from Steven Foung (28) . AR3C was a kind gift from Mansun Law (3). The HIV-1 p24 hybridoma (183-H12-5C) reagent (MAb183) was obtained from Bruce Chesebro through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH (29) .
The VH and VL domains of HC84.1 and HC84.27 were constructed by gene synthesis using sequences reported under PDB accession numbers 4JZN and 4JZO (30) , respectively. The VL and VH regions were subcloned into pcDNA3-tPA-LC and pcDNA3-tPA-HC, respectively, for the expression of IgG1 under the direction of a tissue plasminogen activator (tPA) leader sequence. Antibodies were expressed by transfection of HEK293T cells and purified from the supernatant fluid by using protein G-Sepharose (PGS).
Anti-NS5A antibody from mouse hybridoma 9E10 was a kind gift from Charles Rice (31) . Anti-Myc epitope tag antibody from clone 9E10 is commercially available. Rabbit anti-6ϫHis antibody was purchased (Rockland Immunochemicals, Inc., PA, USA). Horseradish peroxidaseconjugated antibodies were purchased (Dako, Glostrup, Denmark). Fluorescently conjugated antibodies were purchased (Life Technologies, CA, USA).
Ethics. All procedures were performed in accordance with animal ethics guidelines set out by the National Health and Medical Research Council of Australia under ethics approval numbers 996 (CSL Ltd. animal ethics committee) and E/0585/2007/F (Alfred Medical Research and Education Precinct animal ethics committee).
MAb production. BALB/c mice were immunized with a single dose of 20 g of H77c E2 661 (MAb25 to MAb50) or ⌬123 (MAb1 to MAb23) protein in Iscomatrix adjuvant. Animals were euthanized 2 weeks later, and spleens were collected to obtain lymphocytes for fusion with SP-2 myeloma cells. One MAb (MAb24) was generated by vaccinating BALB/c mice with 20 g ⌬123 in Iscomatrix adjuvant once, followed by two further 20-g ⌬123 vaccinations in alum. Three months later, the mice were injected in the tail vein once with 20 g ⌬123 in saline. One week later, the mice were euthanized, and spleens were removed for hybridoma production as described above. Primary cloning of positive hybridomas was performed by limiting dilution in media containing 100 M hypoxanthine and 16 M thymidine using a BALB/c feeder layer. Secondary cloning of positive hybridomas was then performed to generate 48 MAbs. Concentrated solutions of 18 MAbs were produced by using a MiniPerm apparatus. MAbs were isotyped by using the IsoStrip kit according to the manufacturer's recommendations (Roche, Mannheim, Germany).
Radioimmunoprecipitation of E1E2 and Western blotting. Radioimmunoprecipitation (RIP) was performed as described previously (21) . Briefly, HEK293T cells were transfected with plasmid pE1E2H77c and biosynthetically labeled 24 h later by using 150 Ci per well of SLabel, and RIPs were performed as described previously (21) . E1E2 glycoproteins were separated in 10 to 15% SDS-PAGE gels under reducing conditions, and radiolabeled proteins were visualized by phosphorimaging. Western blots were performed on reduced H77c E2 661 run in SDS-PAGE gels and transferred onto nitrocellulose. Blots were probed with MAb, and bound antibody was detected with goat anti-mouse antibody conjugated to Alexa 680 (Life Technologies, CA, USA) by using a Li-COR Odyssey imaging system (Li-COR BioSciences).
Protein purification. MAbs were purified by using PGS beads (Genscript, USA). MAbs bound to PGS beads were then washed three times with 1ϫ wash buffer (0.5 M NaCl, 0.05 M Tris [pH 7.4], 1 mM EDTA, 0.02% sodium azide, and 1% Triton X-100) and three times with phosphate-buffered saline (PBS). MAbs were dissociated from the PGS beads by the addition of 0.1 M glycine buffer (pH 2.7) and immediately neutralized by the addition of 1 M Tris-HCl buffer (pH 8.0). The concentration of MAbs was determined by using the Micro-BCA protein estimation kit according to the manufacturer's recommendations (Thermo Scientific, Rockford, IL, USA).
Secreted E2 661 protein in tissue culture fluid was purified by immobilized metal affinity chromatography using nickel Sepharose (GE Healthcare Life Sciences, United Kingdom) according to the manufacturer's instructions. Eluted proteins were dialyzed into PBS, and their concentrations were determined by using the Bradford assay with bovine serum albumin (BSA) as a standard curve (32) . Recombinant dimeric MBP-LEL 113-201 was purified as described previously (19) . For VLPs, tissue culture fluid was collected at 72 h posttransfection, and virions were pelleted through a 25% sucrose cushion and resuspended in PBS. VLPs were assessed via Western blotting after protein separation through a 7.5 to 15% polyacrylamide gradient gel using polyclonal HIV IgG purified from HIV-1-infected individuals, and HCV envelope protein expression was assessed by using anti-E1 (A4) and anti-E2 (H52). Immunoblots were developed by using IRDye 800CW-conjugated rabbit anti-human Ig or Alexa Fluor 680-conjugated goat anti-mouse Ig and scanned by using a Li-COR Odyssey infrared imager.
Direct binding enzyme-linked immunosorbent assays. The reactivity of MAbs to E2 antigens was tested by enzyme-linked immunosorbent assays (ELISAs) using 96-well Maxisorb plates (Nunc, Roskilde, Denmark) coated with 5 g/ml of Galanthus nivalis lectin (GNA-lectin; Sigma, St. Louis, MO, USA) and incubated overnight at 4°C. Unoccupied sites were blocked for 1 h at room temperature (RT) with blocking buffer (1% BSA [Sigma, St. Louis, MO, USA] in PBS). Glycoprotein E2 (5 g/ ml) was then added in diluent buffer (0.5% BSA in PBS containing 0.05% Tween 20 [BSA 5 PBST]) and incubated for 2 h at RT. After washing, serial dilutions of MAbs or rabbit anti-His tag antibody in BSA 5 PBST were applied for 1 h at RT. Bound MAbs were detected by using horseradish peroxidase (HRP)-labeled rabbit anti-mouse or HRP-labeled goat antirabbit in BSA 5 PBST for 1 h at RT, after which plates were developed with the 3,3=,5,5=-tetramethylbenzidine (TMB) substrate (Sigma, St. Louis, MO, USA). The optical densities at 620 nm and 450 nm were measured with a FLUOstar Optima microplate reader (BMG Lab Technologies, Germany).
For ELISAs using VLPs, ELISA plates were coated directly with VLPs in PBS overnight. Unoccupied sites were blocked with PBS containing 1% BSA and 1% skim milk for 1 h at RT. After washes with PBS, MAbs were applied, titrated 0.5 log 10 , and incubated for 2 h at RT. After washes with PBS, rabbit-anti mouse HRP-labeled antibody was added for 1 h at RT, washed with PBS, and then detected with TMB as described above. To detect capsid protein within VLPs, after VLPs were bound to plates, they were permeabilized with 1% Triton X-100 for 15 min. Capsid protein was detected with MAb183, and the ELISA experiment was completed as described above.
Overlapping synthetic 18-mer peptides were used to search for linear epitopes recognized by the MAbs. The 39 overlapping peptides spanning residues 384 to 662 (McKesson Bioservices Corporation, USA) overlap by 11 amino acids and correspond to the sequence of the H77 isolate. A synthetic peptide corresponding to the HVR1 sequence of the H strain, E 384 THVTGGSAGRTTAGLVGLLTPGAKQN 410 , was additionally used to search for anti-HVR1 MAbs (Auspep). ELISA plates were coated directly with each peptide overnight, followed by blocking for 1 h at RT. After four washes with PBST, a single dilution of MAb was added to each peptide-coated well and incubated for 1 h at RT. Bound MAb was detected by using HRP-labeled rabbit anti-mouse antibody and the TMB substrate as described above. Alanine scanning of the MAb24 epitope, covering E2 amino acid residues 411 to 428, was performed by using 18 peptides containing single alanine or serine (position 424) substitutions (Mimotopes, USA). The ELISA was performed as described above.
CD81-E2 binding and binding inhibition assay. Solid-phase immunoassay plates were coated with the dimeric MBP-LEL 113-201 protein (19) (5 g/ml) in PBS overnight, followed by blocking buffer for 1 h at RT. For measurement of direct binding of E2 to CD81, E2 661 glycoproteins were titrated 0.5 log 10 before addition to ELISA plates coated with CD81 and incubated for 1 h at RT. In the case of CD81-E2 binding inhibition assays, MAbs were titrated 0.5 log 10 in diluent and admixed with 50 ng E2 661 glycoproteins, and the antibody-antigen mixtures were added to plates coated with CD81 and incubated for 1 h at RT. Bound E2 was detected by using rabbit anti-His tag antibody for 1 h at RT, followed by HRPlabeled goat anti-rabbit for 1 h at RT and the TMB substrate, as described above.
Neutralization assays. The production of infectious HCVpp was performed as described previously (21) . Briefly, HEK293T cells were cotransfected with 1 g each of pE1E2H77c and pNL4-3.LUC.R-E. Seventy-two hours later, tissue culture fluid was collected and filtered through a 0.45-m syringe filter. To perform NAb assays, serial dilutions of MAb were added to HCVpp and incubated for 1 h at 37°C before addition to Huh7.5 cells seeded 24 h earlier at 30,000 cells/well in 48-well plates. After 4 h of incubation at 37°C, the inoculum was removed and replaced with DMF10NEAA for 72 h. Cells were washed with PBS before lysis in cell culture lysis buffer (Promega, Madison WI, USA). Luciferase activity in clarified lysates was measured by using a luciferase substrate (Promega, Madison, WI, USA) and a FLUOstar Optima microplate reader fitted with luminescence optics (BMG Lab Technologies, Germany).
Infectious HCVcc were produced by transfecting Huh7.5 cells with in vitro-transcribed RNA as described previously (33) . Transfection was performed by using DMRIE-C reagent (Invitrogen, CA, USA). Tissue culture fluid collected 96 h later was filtered through 0.45-m syringe filters and stored at Ϫ80°C. Neutralization assays were performed by mixing HCVcc with an equal amount of serially diluted MAb. The virus-MAb mixture was incubated for 1 h at 37°C before addition to Huh7.5 cells, seeded 24 h earlier at 30,000 cells/well in 48-well plates, for 4 h. Cells were washed 4 times, replenished with fresh DMF10NEAA, and incubated for a further 48 to 72 h. Inhibition of HCVcc entry into target cells by MAbs was determined by measuring luciferase activity.
Sequencing of the IgG-Fv region. Total RNA was extracted from ϳ1 ϫ 10 6 hybridoma cells by using an RNeasy kit (Qiagen, Limburg, Netherlands). cDNAs of heavy chain (VH) and light chain (VL) variable region genes were amplified by using a Superscript III One-Step reverse transcription-PCR (RT-PCR) system with Platinum Taq DNA polymerase (Invitrogen, MA, USA). The cDNA of the heavy chain variable region was amplified by using primers 5=-AG GTS MAR CTG CAG SAG TCW GG-3= and 5=-TGA GGA GAC GGT GAC CGT GGT CCC TTG GCC CC-3=, and the light chain variable region was amplified by using primers 5=-GGT GCA TGC GGA TAC AGT TGG TGC AGC ATC-3= and 5=-GG GAG CTC GAY ATT GTG MTS ACM CAR WCT MCA-3=. Amplified cDNA for both the VH and VL regions was used directly for sequencing. Amino acid alignment was performed with previously reported VH and VL sequences by using ClustalW2 on the EBI website (http://www.ebi.ac .uk/Tools/msa/clustalw2/), where framework regions (FWRs) and complementarity-determining regions (CDRs) were allocated accordingly with manual adjustment (34) .
Surface plasmon resonance. All experiments were performed by using a Biacore 2000 unit (GE Healthcare Life Sciences, United Kingdom). Protein ligands were buffer exchanged into 10 mM sodium acetate (pH 4.2) prior to immobilization on a CM5 chip (GE Healthcare Life Sciences, United Kingdom) via amine-coupling methods to obtain ϳ800 response units (RU). Immobilizations were performed in 1ϫ HBS-N buffer (0.01 M HEPES, 0.15 M NaCl, 3 mM EDTA). For all experiments, a negativecontrol ligand was immobilized in the preceding flow cell, or alternatively, negative-control analyte injection was used to allow subtraction for nonspecific binding. Kinetic experiments were performed at a flow rate of 10 l/min in HBS-EP buffer (0.01 M HEPES, 0.15 M NaCl, 3 mM EDTA, 0.05% Tween 20) . Protein analytes were injected into the system at 4 to 5 serial 2-fold dilutions in HBS-EP buffer with a starting concentration of 0.1 mg/ml. Injections were performed for 250 s to obtain an association rate and were allowed to dissociate for 600 s. An independent loading control at the midpoint concentration was included to ensure concentration accuracy. Regeneration between each cycle was performed at a flow rate of 100 l/min and involved two 15-l pulses of 100 mM phosphoric acid.
RESULTS
To examine antigenic differences between E2 661 and variants of E2 661 wherein HVR1, HVR2, and/or the igVR was deleted, we used 18 novel murine MAbs raised to either E2 661 or ⌬123 and previously characterized MAbs isolated from HCV-infected humans.
Characterization of the epitopes recognized by murine antibodies. We first characterized the 18 MAbs raised to either ⌬123 or E2 661 . Initially, we examined the ability of the MAbs to immunoprecipitate E1E2 heterodimers from transfected HEK293T cells. The results show that all of the MAbs were able to immunoprecipitate E2 and coprecipitate multiple different glycoforms of E1 at similar ratios ( Fig. 2A) . The MAbs were also tested for their ability to recognize denatured E2 661 in a Western blot. MAbs 6, 13, 22, 24, 26, 33, 36, 39 , and 44 bound strongly to denatured E2 661 , suggesting that their epitopes are contained within a continuous E2 sequence, while a small degree of binding above background was detected for MAbs 14, 23, and 25 (Fig. 2B) . A library of overlapping 18-mer peptides derived from genotype 1a strain H77 was used in an ELISA to map the continuous MAb epitopes. The results show that MAb24 binds to an epitope within residues 407 to 424; MAb25, -39, and -44 bind to an epitope within residues 512 to 529; and MAb26 binds to an epitope within residues 645 to 662 (Fig. 2C ). An elongated 27-residue synthetic peptide for HVR1 (residues 384 to 410) corresponding to the H sequence (differs from H77 at N391S) was also used in a direct binding ELISA with MAbs elicited by WT E2 661 . Only MAb36 bound strongly to the 27-mer HVR1 peptide, indicating that its epitope is contained within an HVR1 sequence not represented by the shorter peptides used in this library (Fig. 2D) .
Further epitope mapping was performed by constructing a library of E2 661 mutants targeting residues within known CD81 binding regions or previously described antibody epitopes ( Table  1) . Three of these regions, spanning residues 411 to 428, 430 to 451, and 523 to 549, overlap previously described antigenic regions and were designated epitope I, epitope II, and epitope III, respectively ( Fig. 1A and B) . The E2 661 proteins were expressed in HEK293T cells and concentrated from the tissue culture fluid. The amount of E2 661 used to coat ELISA plates was standardized by using anti-His antibody in ELISAs. The majority of mutations did not affect the binding of conformation-dependent antibody H53 or CBH-7, indicating that the overall global fold was maintained. The exceptions were mutations N540A and W549A, which reduced H53 and CBH-7 binding. However, mutations N540A and W549A did not affect the binding of the majority of antibodies within our panel, consistent with these amino acids being part of the H53 and CBH-7 epitopes, as described previously (35, 36) . The results of E2 661 mutant-MAb binding studies reveal that the binding ability of MAbs 6, 13, 14, 22, 23, 25, 39 , and 44 was affected by mutations within the region spanning epitope III (Table  1) . Two antibodies, MAb24 and MAb33, were affected by mutations in epitope I ( Table 1 ). The binding of MAb26, whose epitope is contained in the region spanning residues 645 to 661, was reduced ϳ50% by the G436A mutation in epitope II (Table 1) . Six MAbs (MAbs 1, 7, 10, 12, and 23) could not be mapped by using this method due to poor reactivity with the relatively low concentrations of E2 661 proteins used for this method (not shown). In addition, we examined the ability of the E2 661 mutants to bind recombinant CD81 MBP-LEL . Mutations that reduce binding to CD81 include those at W420, H421, S424, L427, N430, G436, W437, L438, A439, G440, L441, F442, Y443, G523, P525, Y527, W529A, G530, D535, N540, W549, Y613, and Y616 (Table 1) .
Reactivity of MAbs to intact E2 661 and E2 661 proteins containing variable region deletions. We examined whether the reactivity of antibodies to E2 661 was modulated by the presence of the variable regions. A solid-phase assay was used to assess the binding of MAbs to WT E2 661 and E2 661 containing deletions of HVR1 (⌬1), HVR2 (⌬2), the igVR (⌬3), or combinations thereof (⌬12, ⌬13, ⌬23, and ⌬123) (12) . First, equivalent coating levels for all antigens were confirmed by using an antibody to the C-ter-minal six-histidine tag (anti-His) (Fig. 3) . MAbs 6, 13, 14, 22, 23, 24, 25, 26, 39 , and 44 reacted equally to all antigens; binding curves for E2 661 and ⌬123 are shown in Fig. 3 , and the apparent affinities of binding calculated for each MAb against each antigen are shown in Table 2 . However, the reactivity of MAbs 1, 7, 12, 16, and 20, all raised to ⌬123, was at least 2-fold lower for E2 661 than for ⌬123 ( Fig. 3 and Table 2 ). In the case of MAbs 1, 7, 12, 16, and 20, improved binding was observed when any one of the variable regions was deleted (Table 2 ). In the case of HVR1-specific MAb36, deletion of HVR1, individually or in combination with other variable region deletions, ablated binding (Fig. 3) . Deletion of HVR1 also blocked conformation-independent MAb33 bind- 661 . Nickel affinity-purified E2 661 was subjected to reducing SDS-PAGE and transferred onto nitrocellulose. Strips were probed with each MAb, followed by detection with anti-mouse Alexa 680-labeled antibody and infrared analysis (Li-COR Odyssey). The antigens to which the MAbs were raised are indicated above the gel. (C) Overlapping-peptide scan of antibodies reactive to denatured E2 661 . Synthetic 18-mers, overlapping the H77c E2 sequence by 11 amino acids, were used in a direct binding ELISA. Binding to a peptide is shown in gray and represents at least 10 times the background level. (D) Ability of MAbs raised to WT E2 661 to recognize an extended HVR1 peptide of strain H. Antibodies were applied to plates coated with peptide and titrated 0.5 log 10 .
ing to E2 661 , suggesting that its epitope includes residues in HVR1 as well as L413 in epitope I (Fig. 3 and Tables 1 and 2 ). Deletion of the igVR alone (⌬3) resulted in a complete or partial loss of reactivity for MAb33 or MAb36, respectively. However, deletion of the igVR together with HVR2 (⌬23) improved MAb33 and MAb36 binding, indicating that their epitopes do not directly include residues from the igVR but that their epitopes are affected by a conformation induced by the isolated deletion of the igVR from E2 661 . We also examined whether binding to E2 661 was modulated by variable regions using previously described human MAbs HC1, HC84.1, HC84.22, HC84.27, and AR3C. The level of binding to ⌬123 for HC1, HC84.22, and AR3C was Ͼ1.5-fold higher than the binding toward WT E2 661 (Fig. 3 and Table 2 ). These results suggest that all three variable regions modulate the exposure of antibody epitopes on the E2 core domain.
Ability of MAbs to inhibit interaction with CD81. Hepatitis C two independent experiments. Percent binding was calculated relative to the binding observed for WT E2 661 . Nonlinear regression analysis was performed with Prism v 6.0f. Data from two independent analyses of MAb24 reactivity are shown for reproducibility. The amounts of E2 661 containing single and multiple deletions of the variable regions added to plates were equivalent, as indicated by GNA-lectin capture of proteins followed by detection with an antibody to the 6ϫHis epitope tag (anti-His) from two independent analyses performed three times (means Ϯ standard deviations).
virus-mediated entry requires an interaction between glycoprotein E2 and the LEL of the surface tetraspanin CD81. Antibodies with the ability to prevent this interaction can also have the capacity to neutralize virus entry. We examined whether any of the antibodies were able to prevent the interaction between E2 and CD81 using a dimeric form of the LEL, MBP-LEL 113-201 , previously used to define the E2 binding site (19 were able to inhibit E2 binding to CD81 (Fig. 4 and Table 3 ). Three antibodies, MAbs 10, 39, and 44, showed similar abilities to inhibit E2 661 and ⌬123 binding to CD81. In contrast, MAbs 1, 7, 12, 16, 20, and 24 showed a stronger inhibitory capacity against ⌬123, with the most striking example being MAb7 (raised to ⌬123), which failed to block E2 661 -CD81 binding while completely inhibiting ⌬123-CD81 binding (50% inhibitory concentration [IC 50 ] of 2 g/ml) (Fig. 4 and Table 3) . Conversely, MAb33, whose epitope involves residues in HVR1 as well as L413, moderately inhibited the binding of E2 661 to CD81 (IC 50 of 16 g/ml) but failed to block ⌬123-CD81 binding, consistent with the deletion of HVR1 from the latter construct ( Fig. 4A and Table 3 ). The ability of MAb24, specific to epitope I, to inhibit E2-CD81 binding was 10-fold greater for ⌬123 than for E2 661 . Monoclonal antibodies isolated from HCV-infected humans, AR3C, HC1, HC84.1, HC84.22, and HC84.27, also demonstrated a greater capacity to inhibit ⌬123-CD81 binding, suggesting that this property is not unique to the use of E2 661 or ⌬123 for MAb production and is a feature of antibodies isolated from infected humans also (Fig. 4A) . We examined whether the data could be influenced by a difference in the binding of the E2 661 proteins to CD81 using MBP-LEL 113-201 . Our previous study determined an affinity of ϳ30 nM for the E2 661 -MBP-LEL 113-201 interaction in a competition ELISA (19) . Using a solid-phase binding assay, affinity-purified E2 661 with one or two variable regions deleted displayed similar binding to MBP-LEL 113-201 and was even slightly improved for ⌬123, relative to WT E2 661 binding (Fig. 4B) . Biosensor analysis of the binding of E2 661 proteins to MBP-LEL 113-201 was also performed (Fig. 4C) . Although the maximum response units (RU) varied between the deletions due to different concentrations of the functional monomer in individual protein preparations, they all displayed association and dissociation curves similar to those of the WT E2 661 protein and deletants, indicating that they share similar binding kinetics (Fig. 4C) . Global fitting of the concentrationindependent dissociation rates (k off ) also demonstrated that each of the deletion constructs retained high-affinity (k off ϭ 10 Ϫ3 s) binding to MBP-LEL (Table 4 ). These data suggest that de- (Fig. 1B) . d Ϫ, Ͼ1 g/ml required to achieve an optical density of 0.1 units; ϩ, 1 to 0.1 g/ml required; ϩϩ, 0.1 to 0.01 g/ml required; ϩϩϩ, Ͻ0.01 g/ml required (Fig. 5) . e For neutralization, the IC 50 was calculated against HCVpp incorporating genotype 1a E1E2 glycoproteins in a 6-point dilution curve performed in triplicate. Ͼ, 50% neutralization not achieved. f Epitope mapping data derived from Table 1 and Fig. 2 . NM, not mapped. (18) a The IC 50 for E2-CD81 inhibition was calculated from the means of data from at least two independent experiments, and the fold increases in IC 50 values relative to those for ⌬123 are shown in parentheses. Ͼ denotes that 50% inhibition was not achieved. Data were derived from an analysis independent of those for Fig. 4A and Table 3 . b Global fitting of the data was performed by using BiaEvaluation software to determine the off rate, and 2 values are shown in parentheses.
letion of the individual (or multiple) variable regions does not substantially alter the MBP-LEL 113-201 binding affinity (or kinetics of binding), and so cannot account for the differences in the abilities of these MAbs to inhibit the E2-CD81 interaction. These results suggest that the variable regions of E2 modulate the accessibility of epitopes within the core domain of E2, thereby interfering with the ability of antibodies to inhibit the interaction between E2 and CD81.
Variable regions modulate the accessibility of MAb epitopes in the CD81 binding site on E2 661 . We further examined the contribution of each variable region of E2 to modulating the accessibility of epitopes recognized by MAbs capable of blocking E2-CD81 binding using single (⌬1, ⌬2, and ⌬3) and double (⌬12, ⌬13, and ⌬23) variable region deletants in addition to E2 661 and ⌬123 (12) . MAbs 24 and 7 were examined because they showed a Ͼ10-fold difference in their ability to inhibit binding of E2 661 to CD81 versus binding of ⌬123 to CD81.
Removal of HVR1 together with either HVR2 (⌬12) or the igVR (⌬13), removal of HVR2 and the igVR (⌬23), or removal of all three variable regions at once (⌬123) increased the ability of MAb24 to inhibit E2-CD81 binding at similar levels (Table 4) . Removal of only one variable region (⌬1, ⌬2, or ⌬3) resulted in intermediate levels of inhibition. These differences are not explained by a difference in the binding preferences of MAb24 for different E2 661 antigens (Table 2 ). In addition, the dissociation rates of E2 661 and deletants with CD81 differed by Ͻ2-fold ( Fig. 4B and Table 4 ) and cannot account for the Ն4-fold differences in the ability of MAb24 to inhibit ⌬1, ⌬2, ⌬3, and WT E2 661 binding to CD81. MAb7 was unable to inhibit CD81 binding by either E2 661 or E2 661 containing HVR2 and the igVR (⌬1) ( Table 4) . However, deletion of all three variable regions (⌬123), HVR1 plus the igVR (⌬13), or HVR2 plus the igVR (⌬23) resulted in markedly increased inhibitory activity, whereas deletion of HVR1 plus HVR2 (⌬12), HVR2 (⌬2), or the igVR alone (⌬3) had an intermediate effect (Table 4 ). MAb7 shows a preference for binding E2 661 when one or more variable regions are deleted, as we observed a 2-fold increase in apparent affinity, which may in part account for these differences in E2-CD81 inhibition (Table 2 ) but does not explain the failure of MAb7 to inhibit ⌬1-CD81 interactions. Furthermore, this pattern of inhibition does not correlate with dissociation rates for E2 binding to CD81 and are distinct from the IC 50 s obtained by using MAb24. These data suggest that the epitope of MAb7 is occluded by HVR2 and the igVR and that deletion of both is necessary to reveal its ability to inhibit E2-CD81 binding. Overall, the variable regions modulate the accessibility of the antibody epitopes of MAbs 24 and 7 and can influence their ability to block the interaction between E2 and CD81.
Ability of antibodies to recognize epitopes on virus-like particles. To examine whether the antibodies were able to bind their epitopes on E1E2 glycoproteins present on viral particles, a solidphase ELISA was employed, where VLPs were bound to plates and all steps were performed in the absence of detergent. The pelleted VLPs contained E1 and E2 glycoproteins as well as the components of the HIV capsid (Fig. 5A) . The ELISA results show that anticapsid antibody binding was enhanced 4-fold only if VLPs were permeabilized with Triton X-100, confirming that VLPs were largely intact in the absence of detergent (Fig. 5B) . No binding was observed by using an irrelevant antibody or in the absence of primary antibody (Fig. 5B) . A high level of binding of MAbs 6, 13, 14, 22, 24, 25, 26, 33 , and 39 to intact VLPs was observed, suggesting that their epitopes are highly accessible in VLP-incorporated E1E2, while MAbs 23, 36, and 44 showed an intermediate level of reactivity ( Fig. 5C and Table 3 ). The remaining MAbs, MAbs 1, 7, 10, 12, 16, and 20, reacted weakly or not at all to VLPs, suggesting that their epitopes are occluded in the structure of E1E2 on VLPs (Fig. 5C and Table 3 ) and correlating with a weaker ability to immunoprecipitate E1E2 complexes from cell lysates (Fig. 2) . This subset of antibodies correlates with those that could not be mapped by using an E2 661 mutant panel and with a binding preference for E2 containing at least one variable region deletion, suggesting that their epitopes are occluded in solubilized E1E2 and VLPs.
Ability of MAbs to neutralize HCV. To date, two major specificity classes have been identified for HCV NAbs that recognize E2. The first class comprises those antibodies that are specific to HVR1, which usually mediate type-specific neutralization, with little or no cross-reactivity with heterologous genotypes or subtypes. The second class comprises NAbs that can prevent the interaction between E2 and CD81; such NAbs are sometimes able to neutralize more than one genotype of HCV. The cross-reactivity of MAbs toward the 6 major genotypes of HCV was examined in a direct binding ELISA using genotype 1 to 6 E2 661 proteins secreted from transfected HEK293T cells. The results show that MAbs 1, 12, 16, 20, 36, 39 , and 44 were entirely specific to genotype 1a E2 661 , while MAbs 6, 13, 14, 22, 23, and 24 were completely cross-reactive against all 6 genotypes. The remaining MAbs had variable cross-reactivity to heterologous genotypes (Table 3) .
The neutralization abilities of MAbs were examined with retroviral luciferase reporter particles pseudotyped with genotype 1a H77c E1E2 (HCVpp). Five of the 18 MAbs, MAb10, MAb24, MAb33, MAb36, and MAb44, showed at least 50% neutralization against homologous H77c HCVpp (Table 3) . The neutralizing abilities of these MAbs correlated with their ability to inhibit E2 binding to CD81 (MAbs 10, 24, 33, and 44) or HVR1 reactivity (MAb36). Six MAbs that inhibited the E2-CD81 interaction were unable to prevent Ͼ50% of homologous HCVpp entry (not shown).
Neutralizing MAb24 was able to recognize E2 661 proteins of 6 HCV genotypes. We therefore examined the ability of MAb24 to mediate cross-genotype neutralization using either HCVpp or HCVcc. The IC 50 of MAb24 against homologous genotype 1a HCVpp was found to be 6 g/ml, with cross-neutralizing activity against genotype 2a, 3a, 4a, 5a, 6a, and 7a viruses being detected (Fig. 6A) . However, 90% neutralizing activity was observed only against genotype 1a, 2a, 4a, and 5a viruses (Fig. 6A) . MAb24, specific to epitope I, overlaps an epitope recognized by other broadly reactive antibodies, AP33, HCV1, and 3/11 (34, 37, 38) . The IC 50 of MAb24 against H77 HCVpp is similar to that of AP33 (1 g/ml) (37) but higher than that of HCV1 (1 nM) (38) . The use of E2 661 mutants indicated that the epitope of MAb24 includes residues L413, N415, G418, W420, and H421 (Table 1 ). An alanine scan of the synthetic peptide spanning residues 411 to 428 confirmed these results and identified additional mutations, I414A and T416A, which substantially reduced MAb24 binding in the context of a peptide (Fig. 6B) . A comparison of MAb24 with antibodies whose epitopes are also located within this region is shown in Fig. 6C . Common to all antibodies that bind the region spanning residues 411 to 428 is the recognition of N415 and W420. What distinguishes MAb24 from previously described MAbs to this region is its sensitivity to mutations at I414 and T416 as well as those at H421 (Fig. 6C) . While this region is well conserved across each of the representative members of the 7 genotypes, variation at I414 and T416 is observed (Fig. 6D) .
MAb33 cross-reacted with E2 proteins of genotypes 4a and 6a. We therefore tested its ability to mediate cross-genotype neutralization and found that it weakly neutralized genotype 4a, 6a, and 7a viruses, with IC 50 s of 52 g/ml, 78 g/ml, and 78 g/ml, respectively, but failed to reach 90% inhibition.
Comparison of the VH and VL sequences of MAb24 with those of analogous MAbs. To examine whether the mechanism of MAb24 binding to E2 and its ability to cross-neutralize diverse strains of HCV resembled those of other MAbs recognizing this region of E2, the amino acid sequences of the variable light and variable heavy chain regions of MAb24 were aligned with those of AP33 ( Fig. 7A and B) . Sequences of MAb24 and murine AP33 are similar, with the following exceptions. In VL, CDR1 has 3 amino acid changes (G27S VL , N30K VL , and F36Y VL ), CDR2 contains one amino acid change (N55E VL ), and CDR3 contains 2 changes (Q89H VL and V92E VL ). In the VH sequence, CDR1 is identical to AP33. However, CDR2 contains 3 changes (S56D VH , L61P VH , and R64K VH ), and CDR3 is elongated and differs at each position with respect to AP33. The most likely germ lines from which MAb24 has evolved are IGKV3-10*01 F (96% identical), IGKJ1*01 (100% identical), IGHV3-8*02 F (96.49% identical), IGHJ3*01 F or IGHJ3*02 P (79.17% identical), and IGHD3-2*01. Comparison of MAb24 with MAb AP33 reveals that the same germ line ancestors are used for both the VH and VL genes but that a different VH J gene is used for AP33, IGHJ4*01 F.
The structure of AP33 was used to map specific features of MAb24 ( Fig. 7A and B) . Most residues that delimit the peptide binding pocket are conserved, suggesting that they play a similar role in MAb24 (Tyr28 VL , Phe32 VL , Asn91/Asn92 VL , Trp96 VL , and Tyr33-50-53-58 VH ). The most significant differences are located in the heavy chain of CDR3, which is longer by 1 residue in MAb24 and has little sequence similarity with that of AP33. In particular, the three contact residues Ile95 VH , Thr97 VH , and Tyr100 VH are not equivalent in MAb24. The corresponding Met95/Tyr97/ Gln100 VH residues have a similar pharmacophore, although the polar and aromatic residues are swapped in the sequence (Fig. 7A  and B ). High-resolution structural studies will be needed to establish whether this motif also plays a role in the docking of the peptide. Among the other four differences in MAb24 located around the paratope (S56D VH , R64K VH , G27S VL , and N30K VL ), position 27 is notable because of its proximity to CD81 contact residue His421 within E2. In the absence of conformational rearrangements, the hydroxyl group of Ser27 would be only 5 Å away from His421 in the E2 protein, which may explain the increased importance of this residue compared to AP33.
DISCUSSION
Glycoprotein E2 contains three surface-exposed variable regions that can be deleted simultaneously from E2 661 (⌬123) while retaining CD81 binding and NAb epitopes. In this study, we generated 18 new HCV E2-specific MAbs, raised to either ⌬123 or E2 661 , that were used to examine whether HVR1, HVR2, or the igVR affected their ability to recognize antigen or inhibit E2-CD81 interactions. In addition, well-characterized MAbs isolated from HCV-infected humans were examined. These studies reveal that the variable regions affect the ability of both neutralizing and nonneutralizing antibodies to bind their epitopes and modulate their ability to inhibit E2-CD81 interactions.
Five of the new murine MAbs were able to neutralize virus, and neutralization correlated with either HVR1 reactivity or the ability to prevent E2 binding to CD81. Two neutralizing antibody epitopes (MAb33 and MAb36) involved HVR1. Interestingly, deletion of the igVR alone in an HVR1-containing construct (⌬3) substantially reduced binding by these MAbs, suggesting that the conformation and/or accessibility of HVR1 is altered when the igVR is deleted from E2. However, binding was at least partially restored when the igVR and HVR2 were deleted simultaneously (⌬23), suggesting that HVR1, HVR2, and the igVR are structurally linked in E2. Examination of the E2 core structure places the igVR in the vicinity of the HVR2 stem-loop, which is on the opposite face of E2 with respect to the likely location of HVR1 (13, 14) (Fig. 8A) . It is possible that if E2, like other viral envelope glycoproteins, forms dimers or trimers on the surface of virions, intersubunit contacts may place HVR1, HVR2, and the igVR proximal to each other in the quaternary structure, thereby modulating the formation and/or structure of the MAb36 and MAb33 HVR1-dependent epitopes. In turn, sequence changes in HVR2 and the igVR could potentially impact the HVR1 structure and provide an additional mechanism of allosteric modulation of HVR1 neutralization epitopes.
MAb24 recognized the epitope I region of E2, was completely cross-reactive against HCV genotypes 1 to 6 in solid-phase binding assays, and was able to neutralize HCV genotypes 1 to 7 but with a large range of IC 50 s. Epitope I is proximal to the neutralizing face of E2 and contains two CD81 contact residues, W420 and H421 (33, 35) . Binding data obtained with VLPs suggest that it is a highly surface-accessible region in H77c genotype 1a E1E2 glycoproteins. Alanine scanning indicated that W420 and H421, as well L413, N415, and G418, are essential for MAb24 binding. Interestingly, relatively few mutations occur within epitope I in the HCV strains used for neutralization assays here: I414V occurs in geno- types 1b, 2a (J6), 3a, and 6a, while T416S is observed for G4a. However, epitope I sequence conservation did not correlate with neutralization. For example, MAb24 potently neutralized V414-containing G2a strain J6 but poorly neutralized the G6a strain with an identical epitope I sequence. Furthermore, a G7a strain was poorly neutralized by MAb24 despite having an epitope I sequence identical to that of G1a and G5a viruses. These data suggest that the ability of MAb24 to neutralize virus is dependent on sequences external to epitope 1 that may modulate its exposure and/or conformation. Consistent with this idea, removal of HVR1, HVR2, or the igVR improved the ability of MAb24 to inhibit E2-CD81 binding by 3-to 6-fold. We predict that the exposure of the MAb24 epitope and the ability to neutralize virus will therefore be affected by sequence changes in HVR1, HVR2, and the igVR and their ability to occlude epitope I on the surface of virus particles. In the three-dimensional structure of E2, HVR1 is proximal to epitope I (Fig. 1B) , and previous studies demonstrated its ability to modulate CD81 binding (11) . However, HVR2 and the igVR are on the opposite face of E2, and thus, why their presence occludes MAb binding on the neutralizing face remains unclear. Similarly to the proximal HVR1 region, it is possible that occlusion of epitope I by HVR2 and the igVR occurs in the context of E2 dimers or trimers present in virions, but this remains unknown.
In total, 8 MAbs recognized amino acids in epitope III: MAbs 6, 13, 22, 39, and 44 strongly recognized their epitope on denatured E2, while MAbs 14, 23, and 25 recognized a conformation-sensitive epitope and reacted weakly to denatured E2 661 ( Fig. 2B and Table 3 ). In the E2 core domain structure, epitope III overlaps the "CD81 binding loop" (residues 519 to 535) on the neutralizing face of E2 (13), and our panel of E2 661 mutants (Table 1 and Fig.  8B ) indicates that the residues involved in CD81 binding map to the neutralizing face of E2. Consistent with the predicted prominent exposure of this region on virions, all epitope III-specific MAbs recognized E1E2 on the surface of intact VLPs. Two epitope III-specific MAbs (MAbs 39 and 44) inhibited E2 binding to CD81 and were distinguished from noninhibitory MAbs by a requirement for G523 for E2 661 binding. Of these, only MAb44 exhibited neutralizing activity, which appears to correlate with a more extensive epitope involving G523, P525, N540, and W549 in epitope III and Y613 (Fig. 8B) . These data suggest that neutralizing activity is dependent on the engagement of an extensive antibody contact area (including G523 and W549) for effective E2-CD81 blockade (Fig. 8B) . In comparison, the E2 region that was recognized by nonneutralizing/non-E2-CD81-inhibitory epitope III-specific MAbs (i.e., MAbs 6, 13, 14, 22, and 23) only partially overlaps the MAb44 epitope, resulting in an inability to prevent E2-CD81 interactions. Together, the data suggest that the angle of MAb engagement with E2 may be critical in determining its ability to both block E2-CD81 binding and prevent the entry of HCV. Further structural studies similar to those performed by using CD4 binding site antibodies and HIV are required to resolve this question (39, 40) .
Differences in the ability to block E2-CD81 interactions were found to be dependent on the presence of variable regions and were detected for a subset of both the new murine antibodies characterized here and MAbs previously isolated from HCV-infected humans. These differences in inhibitory capacity could not be explained by differences in E2-CD81 binding or the antibody-E2 binding capacity alone. The results suggest that, in addition to HVR1, both HVR2 and the igVR contribute to the occlusion of antibody epitopes and their ability to prevent E2-CD81 interactions. As HVR2 and the igVR are essential components of E1E2 glycoprotein assembly, it was not possible to examine how their deletion affects neutralization. Structures of E2 containing HVR1, HVR2, and the igVR; knowledge of the organization of (E1)E2 on virions; and structures of intact E2 with CD81 are required to resolve how the CD81 site and underlying NAb epitopes are modulated by all three variable regions in recombinant and virion-incorporated forms of E2.
